Warnex Inc.

Warnex Inc.

November 11, 2005 07:01 ET

Warnex signs up Vanderpol's Eggs

LAVAL, QC, Nov. 11 - Warnex Inc. (TSX:WNX) announced today that
Vanderpol's Eggs Ltd., a leading egg producer based in Abbotsford, British
Columbia, has purchased a Warnex™ Rapid Pathogen Detection System to
monitor the safety of its products.

"With leading companies in the beef, pork, turkey, chicken, and dairy
industries already using our technology to ensure the quality of their
products, we can now add the egg industry," said Mark Busgang, President and
CEO of Warnex. "This diversity in our client base demonstrates the broad
applicability of our system and underscores its ultimate market potential."

Established in 1952, Vanderpol's Eggs (www.vanderpolseggs.com) markets
fresh and frozen egg products from commodity whole egg, albumen and yolk to
specialty blends, mixes and sauces as well as cooked egg products. Vanderpol's
passion for the healthy goodness contained within the egg has driven them to
explore and develop new markets and products mainly for the food service and
industrial food markets, as well as nutritional and neutraceutical
ingredients. Currently, their 60 employees produce 18 million pounds of egg
products annually.

"In order to provide our customers with high-quality and healthy
products, we have an HACCP (Hazard Analysis Critical Control Points) program
to ensure the safety and quality of our products," said David Westcott,
Quality Manager of Vanderpol's Eggs. "We will use the Warnex Rapid Pathogen
Detection System to monitor our products at critical stages of production."

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
food sample. The system allows for the simultaneous detection of multiple
pathogens and processing of samples within 12 to 48 hours, a significant
improvement over traditional microbiology tests that currently require 5 to
7 days.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods to
GMO testing. Our development pipeline includes applications in the detection
of viruses, toxins, yeasts, and fungi, as well as meat speciation and
bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and
clinical service groups offer a variety of quality control services, method
development and validation, contract R&D, bioavailability and bioequivalence
studies for clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or

Contact Information